Watch Out For These 5 Dermatology Drugs

Five dermatology drugs are expected to become heavy hitters in the pharmaceutical industry. According to a recent Global Business Intelligence (GBI) report, revenue from the dermatology market is expected to increase from $19.8 billion in 2016 to $36.6 billion in 2023, a compound annual growth rate of 9.13 percent. Cosentyx, Otezla, Eucris, Taltz, and Dupixent are expected to play major roles in the market’s growth.

Cosentyx, Otezla, Eucris, and Taltz have been developed to treat psoriasis. Dupixent is the first biologic to receive approval for atopic dermatitis. According to the report, Dupixent will be the lead revenue producer in its area, as it’s expected to have little competition.

These predictions are a result of the upcoming patent expirations of a series of successful commercial drugs. According to the report, AbbVie’s Risankizumab and Johnson & Johnson’s Guselkumab will enter the market in 2023, but won’t experience the same degree of success, as the aforementioned psoriasis drugs will already have saturated the competition. Regardless, Johnson & Johnson, AbbVie, Amgen, Novartis, and Pfizer still dominate the dermatology therapy industry, and will continue to thrive. Sanofi and Eli Lilly shares will also increase.

“In terms of pipeline products, the dermatology space contains 850 with a disclosed stage of development, but the majority of these are at an early stage,” wrote Ross Wilkinson, GBI associate analyst. “Biosimilars only make up 6 percent of the dermatology pipeline, but are more common at the later phases of clinical development, accounting for 24 percent.”